- $1.03tn
- $1.07tn
- $65.18bn
Brief: Lilly's Foundayo Delivers Superior A1C Control & Weight Loss In Three Type 2 Diabetes Trials
Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market (updated)
Lilly shares jump as analysts see retatrutide data extending obesity market edge
Zealand Pharma shares plunge 24% after survodutide side effects, efficacy disappoint
Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat
Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits
Brief: Novo Nordisk Says People With Type 2 Diabetes Who Were Increased To Semaglutide 2 Mg Were more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
Structure's experimental obesity pill shows no signs of liver injury
Zealand touts promising tolerability data for obesity drug in mid-stage study
Citi calls side effect concerns on Lilly experimental obesity drug "overdone"
Lilly to halve planned €2.3 billion investment in Germany, CEO tells newspaper (updated)
Lilly to halve planned €2.3 billion investment in Germany, CEO tells newspaper
Brief: Ascidian Therapeutics Announces Global Research Collaboration Licensing Agreement With Eli Lilly
Lilly gains license for Ascidian's gene-editing tech to develop kidney disease drugs
Focus: GLP-1 drugs may have a beneficial effect across many types of cancer
Cigna drops coverage of GLP-1 obesity drugs for its own employees
Cigna drops coverage of GLP-1 obesity drugs for its own employees